

Annex 2: Substantial Amendment Form

NOTIFICATION OF A SUBSTANTIAL AMENDMENT TO A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR THE OPINION OF THE ETHICS COMMITTEES IN THE COMMUNITY

For official use:

Date of receiving the request:	Grounds for non acceptance/ negative opinion: ☐ Date:
Date of start of the procedure:	Authorisation / positive opinion: ☐ Date:
Competent authority registration number of the trial: Ethics committee registration number of the trial:	Withdrawal of amendment application ☐ Date:

To be filled in by the applicant:

This form is to be used both for a request to the Competent Authority for authorisation of a **substantial** amendment and to an Ethics Committee for its opinion on a **substantial** amendment. Please indicate the relevant purpose in Section A.

A TYPE OF NOTIFICATION

A.1 Member State in which the substantial amendment is being submitted:	
A.2 Notification for authorisation to the competent authority:	☐
A.3 Notification for an opinion to the ethics committee:	☐
A.4 Notification for information only¹:	☐
A.4.1 To the competent authority	☒
A.4.2 To the Ethics committee	☐

B TRIAL IDENTIFICATION *(When the amendment concerns more than one trial, repeat this form as necessary.)*

B.1 Does the substantial amendment concern several trials involving the same IMP?
yes ☐ no ☒

B.1.1 If yes repeat this section as necessary.

¹ For substantial amendments to information that only the CA has previously assessed (e.g. quality data in most of the MS), the sponsor should not only submit the amendment to the CA but also inform the ethics committee that they have made the notification indicating that it is "for information only". Similarly, the sponsor should inform the CA of any notification of a substantial amendment to information which was previously only assessed by the ethics committee (e.g. facilities for the trial).

Annex 2: Substantial Amendment Form

B.2 EudraCT number: 2007-001036-31

B.3 Full title of the trial: A 2-cohort, multicentre, randomized, double blind (3rd party open), placebo controlled 4-way crossover study to assess the efficacy of single oral doses of PF-0046687 on erectile function in men suffering from erectile dysfunction, using 100mg sildenafil as a positive control.

B.4 Sponsor's protocol code number, version, and date: A8361011, Amended protocol, 21 May 2007

C IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

C.1 Sponsor

C.1.1 Organisation: Pfizer Limited, Ramsgate Road, Sandwich, Kent. CT13 9NJ

C.1.2 Name of person to contact: [REDACTED] (Development Team Leader)

C.1.3 Address: Ramsgate Road, Sandwich, Kent. CT13 9NJ

C.1.4 Telephone number: [REDACTED]

C.1.5 Fax number:

C.1.6 e-mail: [REDACTED]

C.2 Legal representative² of the sponsor in the Community for the purpose of this trial (if different from the sponsor)

C.2.1 Organisation:

C.2.2 Name of person to contact:

C.2.3 Address:

C.2.4 Telephone number:

C.2.5 Fax number:

C.2.6 e-mail

D APPLICANT IDENTIFICATION, (please tick the appropriate box)

D.1 Request for the competent authority

D.1.1 Sponsor



D.1.2 Legal representative of the sponsor



D.1.3 Person or organisation authorised by sponsor to make the application



D.1.4 Complete below:

D.1.4.1 Organisation: Pfizer Limited, Ramsgate Road, Sandwich, Kent. CT13 9NJ

D.1.4.2 Name of person to contact: [REDACTED]

D.1.4.3 Address: Pfizer Limited, IPC 5-1-71, Dorking Road, Surrey, KT20 7NS

D.1.4.4 Telephone number: [REDACTED]

D.1.4.5 Fax number: [REDACTED]

D.1.4.6 E-mail: [REDACTED]

D.2 Request for the Ethics Committee

² As stated in Article 19 of Directive 2001/20/EC.

Annex 2: Substantial Amendment Form

D.2.2	Legal representative of the sponsor	☐
D.2.3	Person or organisation authorised by sponsor to make the application	☐
D.2.4	Investigator in charge of the application if applicable ³ :	
	• Co-ordinating investigator (for multicentre trial)	☐
	• Principal investigator (for single centre trial):	☐
D.2.5	Complete below	
D.2.5.1	Organisation:	
D.2.5.2	Name:	
D.2.5.3	Address:	
D.2.5.4	Telephone number:	
D.2.5.5	Fax number:	
D.2.5.6	E-mail:	

E SUBSTANTIAL AMENDMENT IDENTIFICATION

E.1 Sponsor's substantial amendment code number, version, date for the clinical trial concerned: ()

E.2	Type of substantial amendment	
E.2.1	Amendment to information in the CT application form	yes ☒ no ☐
E.2.2	Amendment to the protocol	yes ☐ no ☐
E.2.3	Amendment to other documents appended to the initial application form	yes ☒ no ☐
E.2.3.1	If yes specify:	
E.2.4	Amendment to other documents or information:	yes ☒ no ☐
E.2.4.1	If yes specify:	
E.2.5	This amendment concerns mainly urgent safety measures already implemented	yes ☐ no ☒
E.2.6	This amendment is to notify a temporary halt of the trial	yes ☐ no ☒
E.2.7	This amendment is to request the restart of the trial	yes ☐ no ☒

E.3	Reasons for the substantial amendment:	
E.3.1	Changes in safety or integrity of trial subjects	yes ☐ no ☐
E.3.2	Changes in interpretation of scientific documents/value of the trial	yes ☐ no ☐
E.3.3	Changes in quality of IMP(s)	yes ☒ no ☐
E.3.4	Changes in conduct or management of the trial	yes ☐ no ☐

³ According to national legislation.

E.3.5	Change or addition of principal investigator(s), co-ordinating investigator	yes ☐	no ☐
E.3.6	Change of sponsor, legal representative, applicant	yes ☐	no ☐
E.3.7	Change/addition of site(s)	yes ☐	no ☐
E.3.8	Change in transfer of major trial related duties	yes ☐	no ☐
E.3.8.1	If yes, specify:		
E.3.9	Other change	yes ☐	no ☐
E.3.9.1	If yes, specify:		
E.3.10	Other case	yes ☐	no ☐
E.3.10.1	If yes, specify:		

E.4 Information on temporary halt of trial			
E.4.1	Date of temporary halt	(YYYY/MM/DD)	
E.4.2	Recruitment has been stopped	yes ☐	no ☐
E.4.3	Treatment has been stopped	yes ☐	no ☐
E.4.4	Number of patients still receiving treatment at time of the temporary halt in the MS concerned by the amendment ()		
E.4.5	What is (are) the reason(s) for the temporary halt?		
E.4.5.1	Safety	yes ☐	no ☐
E.4.5.2	Lack of efficacy	yes ☐	no ☐
E.4.5.3	Other	yes ☐	no ☐
E.4.5.3.1	If yes to other, specify:		
E.4.6	Briefly describe (free text):		
	- Justification for a temporary halt of the trial - The proposed management of patients receiving treatment at time of the halt (<i>free text</i>) - The consequences of the temporary halt for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product (<i>free text</i>).		

F REASONS FOR SUBSTANTIAL AMENDMENT (one or two sentences):

To update the packaging and final release site for the control drug - sildenafil and the placebo for sildenafil.

G BRIEF DESCRIPTION OF THE CHANGES (free text):

In the original quality IMPD, Pfizer Sandwich was erroneously listed as the packaging and final release site for the control drug - sildenafil and the placebo for sildenafil. The packaging and final release is actually being performed by the participating sites in Norway and the UK.

H CHANGE OF CLINICAL TRIAL SITE(S)/INVESTIGATOR(S) IN THE MEMBER STATE CONCERNED BY THIS AMENDMENT

H.1 Type of change H.1.1 Addition of a new site H.1.1.1 Principal investigator (provide details below) H.1.1.1.1 Given name H.1.1.1.2 Middle name (if applicable) H.1.1.1.3 Family name H.1.1.1.4 Qualifications (MD.....) H.1.1.1.5 Professional address H.1.2 Removal of an existing site H.1.2.1 Principal investigator (provide details below) H.1.2.1.1 Given name H.1.2.1.2 Middle name (if applicable) H.1.2.1.3 Family name H.1.2.1.4 Qualifications (MD.....) H.1.2.1.5 Professional address H.1.3 Change of co-ordinating investigator (provide details below of the new coordinating investigator) H.1.3.1 Given name H.1.3.2 Middle name H.1.3.3 Family name H.1.3.4 Qualification (MD.....) H.1.3.5 Professional address H.1.3.6 Indicate the name of the previous co-ordinating investigator: H.1.4 Change of principal investigator at an existing site (provide details below of the new principal investigator) H.1.4.1 Given name H.1.4.2 Middle name H.1.4.3 Family name H.1.4.4 Qualifications (MD.....) H.1.4.5 Professional address H.1.4.6 Indicate the name of the previous principal investigator:
--

I CHANGE OF INSTRUCTIONS TO CA FOR FEEDBACK TO SPONSOR

I.1 Change of e-mail contact for feedback on application*	
I.2 Change to request to receive an .xml copy of CTA data	yes ☐ no ☐
I.2.1 Do you want a .xml file copy of the CTA form data saved on EudraCT?	yes ☐ no ☐
I.2.1.1 If yes provide the email address(es) to which it should be sent (up to 5 addresses):	
I.2.2. Do you want to receive this via password protected link(s) ⁴ ? If you answer no to question I.2.2 the .xml file will be transmitted by less secure e-mail link(s)	yes ☐ no ☐

Annex 2: Substantial Amendment Form

I.2.3 Do you want to stop messages to an email for which they were previously requested?	yes ☐ no ☐
I.2.3.1 If yes provide the e-mail address(es) to which feedback should no longer be sent:	
(*This will only come into effect from the time at which the request is processed in EudraCT).	

⁴ This requires a Eudralink account (see www.eudract.emea.eu.int for details)

J LIST OF THE DOCUMENTS APPENDED TO THE NOTIFICATION FORM

Please submit only relevant documents and/or when applicable make clear references to the ones already submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).

J.1 Covering letter stating the type of amendment and the reason(s)	☒
J.2 Summary of the proposed amendment	☐
J.3 List of modified documents (identity, version, date)	☒
J.4 If applicable, pages with previous and new wording	☐
J.5 Supportive information	☐
J.6 Revised .xml file and copy of initial application form with amended data highlighted	☒
J.7 Comments on any novel aspect of the amendment if any:	☐

K SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

K.1 I hereby confirm that/confirm on behalf of the sponsor that (delete which is not applicable) • The above information given on this request is correct; • The trial will be conducted according to the protocol, national regulation and the principles of good clinical practice; and • It is reasonable for the proposed amendment to be undertaken.
--

K.2 APPLICANT OF THE REQUEST FOR THE COMPETENT	☐
---	--------------------------

PFIZER CONFIDENTIAL

Page 6

Substantial Amendment Form – Version October 2005

Annex 2: Substantial Amendment Form

AUTHORITY (as stated in section C.1):	
K.2.1 Signature ⁵ [REDACTED]	
K.2.2 Print name: [REDACTED]	
K.2.3 Date: 9 th may 2008	

K.3 APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE (as stated in section C.2)	☐
K.3.1 Signature ⁶ :	
K.3.2 Print name:	
K.3.3 Date:	

⁵ On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

⁶ On an application to the Ethics Committee, the applicant to the Ethics Committee needs to sign